BioMarin Pharmaceutical Patent-Cliff Exposure & CMS Drug Spending Portfolio

BioMarin Pharmaceutical (San Rafael, CA): 7 reconciled FDA prescription therapies (7.4% 2025 to 2030 cliff risk), $331.2M 2024 CMS Part D & Medicaid spend, and 41 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterSan Rafael, CA
Reconciled FDA Portfolio Therapies7
2025 to 2030 Patent-Cliff Revenue Exposure7.4%
Primary Portfolio LOE Date2026-01-01
2024 CMS Total Public Spend$331.2M
2024 Medicare Part D Spend$56.0M
2024 Medicaid Spend$275.2M
California HCAI SB 17 Filings41 WAC filings (max 21.9% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for BioMarin Pharmaceutical across sibling Meru public-data platforms.